Between April 2005 and December 2005, 216 patients (142 inpatients and 74 outpatients) from ten hospitals were enrolled. There were 126 male and 90 female patients (a ratio of 1.4:1). Of the 216 ...

RoxyBond is an abuse-deterrent formulation of immediate-release oxycodone that features a unique abuse-deterrent technology. RoxyBond ™ (oxycodone HCl immediate-release tablets) is now available for ...

This interview addresses the challenges and complexities of developing and manufacturing controlled-release drug formulations. Could you introduce yourself and your expertise in drug development and ...

Soleno intends to submit plans to FDA to conduct further analyses of clinical data from completed and ongoing studies of DCCR, together with external, natural history studies REDWOOD CITY, Calif., Dec ...

In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets (R-107) in adult ...

Background and Objective: Oxycodone is a semisynthetic opioid analgesic drug classed as a strong opioid. The controlled-release oxycodone tablet formulation (OCRT) was approved in China in 2004 for ...